Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 3/20 | 0.58 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.54 |
| ▸ | ADK | P55263 | 2/20 | 0.48 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.43 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873612 | 1.00 | PRMT5 (0.58) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL14089358 | 0.91 | ADORA3 (0.57) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL13598817 | 0.91 | ADORA3 (0.57) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL4430766 | 0.91 | ADORA3 (0.57) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL13598664 | 0.91 | ADORA3 (0.57) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL4432672 | 0.89 | ADORA3 (0.55) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL13598665 | 0.89 | ADORA3 (0.55) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL14089611 | 0.89 | ADORA3 (0.55) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL733121 | 0.88 | ADORA3 (0.66) | PRMT5WDR77ADORA3ADORA2AADORA1 | |
| SCHEMBL14782094 | 0.88 | ADORA3 (0.66) | PRMT5WDR77ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476169-B1 | Inhibiting orthopoxvirus replication with nucleoside compounds | MERCK SHARP & DOHME (US) | 2013-03-20 | — | — | EP | claimed |
| US-7323453-B2 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK & CO., INC. (US) | 2008-01-29 | — | — | US | claimed |
| US-20070275912-A1 | Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase | MERCK SHARP & DOHME CORP. | 2007-11-29 | — | — | US | claimed |
| EP-1355916-B1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO INC (US) | 2007-01-10 | — | — | EP | claimed |
| CN-1267446-C | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO INC (US) | 2006-08-02 | — | — | CN | claimed |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN | 2005-12-08 | — | — | US | claimed |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | claimed |
| US-6777395-B2 | VIRICIDES | MERCK & CO., INC. | 2004-08-17 | — | — | US | claimed |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN (US) | 2004-04-15 | — | — | US | claimed |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2004-04-08 | — | — | US | claimed |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2022-11-10 | — | — | US | disclosed |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
| EP-2953461-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-2953462-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | MERCK SHARP & DOHME LLC | 2004-06-10 | — | — | US | disclosed |
| CN-1498221-A | Nucleoside derivatives as inhibitors of RNA-dependent PNA viral polymerase | — | 2004-05-19 | — | — | CN | disclosed |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2004-04-08 | — | — | US | disclosed |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | PRMT5 2225/4885WDR77 2310/4885ADORA3 4434/4885 |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | PRMT5 436/4885WDR77 1478/4885ADORA3 334/4885 |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | NSUN2, NSUN3, POLRMT | PRMT5 352/4885WDR77 1658/4885ADORA3 304/4885 |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | PRMT5 436/4885WDR77 1478/4885ADORA3 334/4885 |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | PRMT5 436/4885WDR77 1478/4885ADORA3 334/4885 |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | PRMT5 436/4885WDR77 1478/4885ADORA3 334/4885 |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | HAVCR2, HCCS, EIF2AK2 | PRMT5 2225/4885WDR77 2310/4885ADORA3 4434/4885 |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | PRMT5 2225/4885WDR77 2310/4885ADORA3 4434/4885 |
| US-20070275912-A1 | Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | PRMT5 436/4885WDR77 1478/4885ADORA3 334/4885 |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | ITPA, PNP, NUDT1 | PRMT5 1470/4885WDR77 1575/4885ADORA3 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.